Genomics Market Overview
Genomics, the study of an individual's genetic material, plays a crucial role in understanding the genetic basis of diseases, developing targeted therapies and enabling precision medicine. The genomics market is experiencing rapid growth and transformation, driven by advancements in technology, decreasing sequencing costs, and the increasing demand for personalized medicine.
The market encompasses various technologies including next-generation sequencing (NGS), polymerase chain reaction (PCR), microarray analysis, and gene editing tools like CRISPR-Cas9. These technologies enable researchers and clinicians to analyze and interpret genetic information, providing valuable insights into disease mechanisms, drug discovery, and patient care.
The genomics market is witnessing significant growth due to the increasing prevalence of genetic disorders, the rising adoption of genomic medicine in clinical practice, and the expanding applications of genomics in areas such as oncology, rare diseases, pharmacogenomics, and agriculture.
Market Growth
The global genomics market size is projected to reach USD 171.41 billion by 2034, expanding from USD 44.72 billion in 2025, at an annual growth rate of 16.1% during the forecast period from 2025 to 2034, as a result of rising technology advancements and increasing demand for personalized medicine.
Genomics Market Trends
- In January 2025, NVIDIA announced new partnerships with Illumina, Mayo Clinic, and Arch Institute to provide NVIDIA AI, accelerating drug discovery and enhancing genomic research, and pioneering advanced healthcare services with agentic and generative AI. The partnership was made to transform the $10 trillion healthcare and life sciences industry.
- In November 2024, the World Health Organization (WHO) issued a set of principles for the ethical collection, access, use, and sharing of human genomic data. These principles can help protect individual rights, promote equity, and foster responsible collaboration in genomic research.
- In October 2024, Accenture announced a collaboration with 1910 Genetics through investment to combine tailored solutions and scalable infrastructure to help clients accelerate drug target identification, reduce costs, and deliver better and more affordable therapies to patients.
Government Initiative
In January 2025, India takes a giant leap in genomics launch of the Indian genomic data set and IBDC portals to empower global research. Making a vital move towards self-reliance in the field of genomics, Dr. Jitendra Singh, Union Minister of State for Science and Technology, announced that India is no longer dependent on foreign genomic data.
SWOT Analysis of Genomics Market
Strengths
- Many market players in the genomics industry have access to state-of-the-art technologies for genome sequencing, analysis, and interpretation. This enables them to provide high-quality genomic data and services to their customers.
- Leading players invest heavily in R&D activities to develop innovative genomic solutions and expand their product portfolios. This allows them to stay at the forefront of technological advancements and maintain a competitive edge.
- Players in the genomics market often establish strategic partnerships and collaborations with research institutions, healthcare providers, and pharmaceutical companies. These collaborations help in knowledge sharing, data exchange, and joint research initiatives, enhancing their market position.
Weaknesses
- The genomics market is characterized by high costs associated with genome sequencing, data analysis, and infrastructure setup. This can pose a barrier to entry for some players and limit their market reach, especially in resource-constrained settings.
- The use of genomic data raises ethical and regulatory concerns, such as privacy, data protection, and consent issues. Market players need to navigate these challenges effectively and ensure compliance with applicable regulations to build trust and maintain their reputation.
Opportunities
- The increasing focus on personalized medicine and precision healthcare presents a significant opportunity for genomics market players. Genomic information is crucial in tailoring treatments and interventions to individual patients, improving treatment efficacy and patient outcomes.
- Genomic data has applications beyond healthcare, including agriculture, biotechnology, forensics, and research. Market players can explore these non-clinical areas to diversify their revenue streams and tap into new market segments.
Threats
- Genomic data is highly sensitive and requires robust data security measures to protect patient privacy and prevent unauthorized access. Any data breaches or privacy concerns can significantly impact the reputation and trust of market players.
- The genomics market is highly competitive, with several established players and new entrants vying for market share. Intense competition can lead to pricing pressures and market saturation, making it challenging for players to differentiate themselves.
Agilent Technologies
Overview
Agilent is a global leader in life sciences, diagnostics, and applied chemical markets. It supports scientists in more than 100 countries with advanced instruments and solutions. The company originated from Hewlett-Packard in 1999 and focuses on improving laboratory efficiency and accuracy.
Quality Products
Agilent provides instruments like chromatography and mass spectrometry systems, software, reagents, and consumables. Its products help in research, clinical diagnostics, and environmental testing.
Recent Update
Agilent recently opened a new biopharma experience center in Hyderabad, India, to strengthen its research and drug-development capabilities.
Bio-Rad Laboratories
Overview
Bio-Rad develops and manufactures products for life science research and clinical diagnostics. It serves laboratories and hospitals worldwide with reliable testing and research tools.
Quality Products
The company offers test kits, reagents, and instruments used for DNA, protein, and cell analysis. It is well-known for its droplet digital PCR technology that provides precise molecular testing.
Recent Update
Bio-Rad reported steady revenue growth in 2025 and continues expanding its digital PCR portfolio for accurate and faster diagnostics.
Danaher Corporation
Overview
Danaher is a science and technology company that designs and manufactures products for life sciences, diagnostics, and biotechnology. It is known for its strong operational system that drives innovation and efficiency.
Quality Products
Danaher’s portfolio includes lab instruments, diagnostic tools, and biotech production systems. Its brands serve industries focused on improving healthcare and research.
Recent Update
Danaher continues to expand its life sciences and diagnostics business through strategic acquisitions to enhance global healthcare outcomes.
Eurofins Scientific
Overview
Eurofins is one of the world’s largest laboratory networks, providing testing and analytical services across food, environment, pharmaceutical, and consumer product sectors.
Quality Products
The company delivers advanced analytical testing, contract research, and safety assurance services to ensure product quality and regulatory compliance.
Recent Update
Eurofins recently expanded its global laboratory operations and digital solutions to improve testing accuracy and turnaround time.
GE Healthcare
Overview
GE Healthcare provides medical technologies and services that enhance patient diagnosis and treatment worldwide. It focuses on imaging, diagnostics, and healthcare digital solutions.
Quality Products
The company offers MRI, CT, and ultrasound systems, along with patient monitoring and life-science tools used by hospitals globally.
Recent Update
GE Healthcare is integrating AI and digital tools into its imaging systems to improve clinical decision-making and patient outcomes.
NVIDIA Corporation
Overview
NVIDIA is a global technology company that develops GPUs and AI platforms. In healthcare, it provides computing solutions for genomics, medical imaging, and drug discovery.
Quality Products
Its AI-based systems help researchers accelerate simulations, analyze biological data, and develop new therapies faster.
Recent Update
NVIDIA continues to collaborate with healthcare organizations to integrate AI in diagnostics and biomedical research.
Oxford Nanopore Technologies
Overview
Oxford Nanopore is a UK-based company that develops portable and scalable DNA and RNA sequencing technologies. It enables researchers to analyze genetic material in real time.
Quality Products
The company’s nanopore sequencers support long-read sequencing, field research, and clinical diagnostics.
Recent Update
Oxford Nanopore is enhancing its sequencing accuracy and cloud-based data analysis tools to support global genomics research.
Thermo Fisher Scientific
Overview
Thermo Fisher is a global leader in serving science, providing innovative laboratory products, analytical instruments, and services to researchers worldwide.
Quality Products
It offers high-quality lab equipment, diagnostic kits, and biotech manufacturing systems used across healthcare and research sectors.
Recent Update
Thermo Fisher recently announced the acquisition of clinical research company Clario to strengthen its drug development and clinical services portfolio.
Recent Developments by Key Market Players
- In February 2023, Roche announced an expansion of its collaboration with Janssen Biotech Inc. The aim of this collaboration is to develop companion diagnostics that can be used alongside targeted therapies.
- In February 2025, Ultima Genomics, Inc. announced the launch of UG 100 Solaris at the Advances in Genome Biology and Technology (AGBT) Conference. The UG 100 Solaris includes new chemistry, software, and simplified workflows for the sequencing platform, resulting in a 50% increase in output and a 20% reduction in prices.
- In April 2025, Valted Seq, Inc., a pioneer in modern biotechnology solutions, announced the launch of a novel AI-powered genomics device, Single Cell AI Discovery Engine (SCADE), designed to revolutionize how researchers and medical care professionals interpret huge amounts of genetic data. By incorporating advanced machine learning algorithms, SCADE promises to radically improve the speed and accuracy of insights derived from genomic sequences, paving the way for faster biomarker and drug discovery, personalized medicine, and more effective treatments for cellular diseases.
- In January 2025, NVIDIA announced new partnerships to transform the $10 trillion healthcare and life sciences industry by hastening drug discovery, enhancing genomic research, and pioneering advanced healthcare services with agentic and generative AI. The convergence of AI, accelerated computing, and biological data is turning healthcare into the largest technology industry.
Recent Developments in the Genomics Market
- In February 2025, Fore Genomics, a leader in pediatric genetic health screening, announced a strategic partnership with Inocras, a leading innovator in whole genome sequencing (WGS) and AI-powered genetic analysis technologies, to enhance Fore’s proprietary pediatric and newborn health screening services.
- In April 2025, GeneDx, a leader in delivering improved health outcomes through genomic insights, announced its plans to acquire Fabric Genomics, a pioneer in AI-powered genomic interpretation. The transaction allows GeneDx’s leadership in the next phase of genomic medicine, decentralized testing with centralized intelligence.
- In February 2025, Singular Genomics Systems, Inc., a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced the closing of its acquisition by an affiliate of Deerfield Management Company, L.P.
- In October 2024, CareDx, Inc. the transplant company a leading precision medicine company focused on the discovery, development, and commercialization of healthcare solutions for transplant patients and caregivers, and Dovetail Genomics, a leader in the field of genomic solutions announced a strategic partnership to drive the next wave of innovation in HLA genotyping for stem cell and organ transplant matching.
- In January 2025, Hendrix Genetics announced the successful closing of the merger between Hypor, its swine genetics division, and Danish Genetics. This strategic combination unites two industry-leading swine genetics organizations under the Hendrix Genetics umbrella, creating a value proposition that sets a new benchmark for the swine industry.
Collaborate with our experts to explore the Genomics Market at sales@towardshealthcare.com
